Claims for Patent: 7,229,967

Summary for Patent: 7,229,967

Title:	Oxygenated albumin for use as blood and blood extender
Abstract:	The compositions described herein comprise oxygenated albumin in an aqueous sterile physiological or serum solution. The albumin is oxygenated to increase the oxygen content up to O.sub.2 saturation with clinically useful oxygen gas. The preferred oxygen-saturated preparations, containing albumin in concentrations from about 5% w/v to about 25% w/v, are useful as clinical resuscitation preparations that release oxygen in a pattern similar to the release of oxygen by whole blood.
Inventor(s):	Ecanow; Bernard V. (Long Grove, IL)
Assignee:	Hunter Research Corporation (Long Grove, IL)
Application Number:	10/987,787
Patent Claims:	1. A method for making a resuscitation fluid containing dissolved oxygen gas which comprises the steps of (a) dispersing about 10% w/v to about 50% w/v human albumin into sterile water to form an aqueous albumin composition; and (b) bubbling oxygen gas through the aqueous albumin composition of step (a) to form oxygenated albumin having an oxygen content that is increased by at least 1% v/v. 2. The method of claim 1, further including the step of storing the oxygenated albumin at a temperature not exceeding about 26.degree. C. 3. The method of claim 1 wherein the concentration of albumin in the aqueous albumin composition is about 10% w/v to about 25% w/v. 4. The method of claim 1 wherein the concentration of albumin in the aqueous albumin composition is about 25% w/v to about 50% w/v. 5. The method of claim 1 wherein the concentration of albumin in the aqueous albumin composition is 12.5% w/v. 6. The method of claim 1 further including the step of adding a vitamin to the resuscitation fluid. 7. The method of claim 1 further including the step of adding an antibiotic to the resuscitation fluid. 8. The method of claim 1 further including the step of adding a nutrient to the resuscitation fluid. 9. The method of claim 1 further including the step of adding a mineral to the resuscitation fluid. 10. A composition comprising an aqueous solution and/or suspension of oxygenated albumin containing 10% w/v to 50% w/v oxygenated albumin. 11. The composition of claim 10 wherein the concentration of albumin in the aqueous albumin composition is about 10% w/v to about 25% w/v. 12. The composition of claim 10 wherein the concentration of albumin in the aqueous albumin composition is about 25% w/v to about 50% w/v. 13. The composition of claim 10, wherein the albumin comprises human serum albumin. 14. The composition of claim 10, wherein the albumin comprises chicken egg albumin. 15. A method of delivering oxygen to a mammal comprising injecting the mammal with an aqueous composition containing water and 10% w/v to 50% w/v oxygenated albumin. 16. The method of claim 15 wherein the concentration of albumin in the aqueous albumin composition is about 10% w/v to about 25% w/v. 17. The method of claim 15 wherein the concentration of albumin in the aqueous albumin composition is about 25% w/v to about 50% w/v. 18. A method of increasing a blood volume of a hemorrhaging mammal comprising injecting the mammal with an aqueous composition comprising water and about 10% w/v to about 50% w/v oxygenated albumin. 19. The method of claim 18 wherein the concentration of albumin in the aqueous albumin composition is about 10% w/v to about 25% w/v. 20. The method of claim 18 wherein the concentration of albumin in the aqueous albumin composition is about 25% w/v to about 50% w/v. 21. A method of treating a burned mammal comprising injecting the mammal with an aqueous composition comprising water and about 10% w/v to about 50% w/v oxygenated albumin. 22. The method of claim 21 wherein the concentration of albumin in the aqueous albumin composition is about 10% w/v to about 25% w/v. 23. The method of claim 21 wherein the concentration of albumin in the aqueous albumin composition is about 25% w/v to about 50% w/v. 24. A method of treating a mammal suffering from a condition selected from the group consisting of hypovolemia, trauma, hypoproteinemia, respiratory distress syndrome, burns, acute gastrointestinal hemorrhage, renal dialysis, erythrocyte resuspension, sequestration of protein-rich fluids, malabsorption, cirrhosis, liver failure, nephrosis, neonatal hemolytic disease, a cerebral vascular accident, and ischemia, comprising injecting the mammal with an aqueous albumin composition comprising water and about 10% w/v to about 50% w/v oxygenated albumin. 25. The method of claim 24 wherein the concentration of albumin in the aqueous albumin composition is about 10% w/v to about 25% w/v. 26. The method of claim 24 wherein the concentration of albumin in the aqueous albumin composition is about 25% w/v to about 50% w/v.

Details for Patent 7,229,967

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2039-09-22
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2039-09-22
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2039-09-22
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2039-09-22
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2039-09-22
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2039-09-22